Yeah, Diddy..get the CAP to research and find as many references as he can to the problem of the day, then start making claims that CDEX has a "product" to cure it, whether or not they do have such a product. The "safe pill system" is a good example.
The next one will very likely be about E Coli on spinich or other salad greens, as Sanddollar suggests. Since we all already have a colony of E COLI living in our tummies (or Colons) it could be a whopper.
Build a salad counter checker to find E Coli on the greens.. Should be worth a billion or two. And make Popeye happy.
///////////////////////////////////////////////////////////////
Here is a "reprint" of the white paper on the Safe Pill System"...
: : WHITE PAPER
Identification of Prescription Medications
The SafePill System (Patents Pending)
1. Introduction
In the medical community the human and economic costs of patients receiving the wrong medication are staggering. This problem is complex, spanning across the entire medical community. The CDEX SafePill System products are designed to significantly minimize the impact of this problem. From a technological perspective, using chemical signatures the SafePill System products will provide virtually real-time and positive identification of solid and liquid medications, along with other information about the medications that may be helpful to a health care provider. Examples of where the SafePill System products can be integrated into the health care system are noted below:
Emergency/First Responder Care Providers: The SafePill System is used when unidentified medications are presented by a patient (or in a first responder case, found on/near the patient) and there is a need to quickly administer medication with assurance that there will not be adverse drug interactions.
Health Care Facilities: The SafePill System is used at one or more stages in the process of obtaining and dispensing medications to provide additional assurance that the correct medications are being administered (e.g., immediately before giving medications to the patient, a SafePill System product could provide positive identification of the medications).
Hospital Pharmacy: The SafePill System is used in the medication disposal process to check the actual content of containers of partially used controlled drugs that are returned for disposal.
The SafePill System products are designed to be fast, to require no operator interpretation, to be stand-alone or capable of integration into existing health care records systems and to provide an immediate printout of results for use by heath care professionals. For example, SafePill-2 could be used in a hospital emergency room during the "check in" process to provide the doctor with a printout identifying the unknown medications (and potential drug interactions) that the patient has in his/her possession (e.g., pillbox). The doctor can then administer other medications with greater assurance of no adverse drug interactions.
2. The Technology
The SafePill System technology is based on CDEX's extensive research and development activities related to detection of explosives and illegal drugs (see results of testing contained on the CDEX web site at www.cdex-inc.com). The CDEX technology that supports the SafePill System uses an ultraviolet energy source to fluoresce the medication(s). Electron decay within the medication(s) causes emission of characteristic photons that through empirically derived algorithms are used as a "fingerprint" to identify the medication(s). The analysis software immediately prints the identity of the medication(s) and other information from nationally recognized sources that would be helpful to the health care worker, e.g., any adverse drug interactions or reactions to known patient allergies.
To date, CDEX has "signatured" and put into its database the so-called "bad actor" drugs --those drugs with likely Hepatic P450 pathway interactions. A second set of approximately 250 drugs is currently being "signatured". The drugs being "signatured" include both liquid and solid forms of medication.
3. Products and Applications
The potential products flowing from the CDEX SafePill System are extensive. CDEX is developing the technology for the medical community in a phased fashion. The currently planned developmental phases are noted below:
SafePill-1: Now available for demonstration, identifies an individual drug from a list of approximately 33 "drugs that may produce serious interactions" (Merck Manual 17th Edition table 301-1). Additionally, SafePill-1 now identifies parenteral controlled substances in syringes and vials and concurrently checks for dilution of returned unused portions as a deterrent to drug diversion. SafePill-1 provides a visual display and printed record identifying the drug(s) and potential interactions.
SafePill-2: Utilizing the SafePill 1 platform, the database will be expanded to include the currently most prescribed drugs and "high risk" medications (approximately an additional 250 drugs). By virtue of the expanded database, SafePill-2 can fill a number of needs in the entire medication cycle including disposal of unused controlled medications. SafePill-2 will also include the ability to compare the identified medications to possible allergic reactions caused by allergies identified by the patient. As needed, SafePill-2 can be formatted to contain a separately optimized version specifically for parental controlled substance tracking and disposal.
SafePill-3 will deploy the SafePill 2 technology into a mobile, hand-held scanner platform similar to the ultraviolet system (PS3) used by CDEX for explosive detection (see the CDEX web site for photographs).
SafePill-4: Utilizing the SafePill 3 platform, the software will provide a printout of additional information for inclusion in the patient's medical record as well as an accessible database of all such information across the facility, e.g., positive identification of the medication along with the date/time of medication and the administering health care provider.
SafePill-5: Using the SafePill-4 platform, modify the system to be able to identify and distinguish medications when combined in groups such as several medications placed in the typical medication cups utilized in hospitals. This application will utilize a CDEX proprietary software suite to individually identify each medication from the resultant complex multi pill spectra.
SafePill-6: Establishes an interface between the identification capabilities of the SafePill-4 or 5 systems and the hospital's database providing assurance that:
The medications administered are the medications prescribed.
The medications are administered to the correct patient.
The medications are administered at the correct interval including a computer generated time and date stamp.
The patients' records are updated automatically.
The hospital's billing database is automatically updated.
CDEX has "signatured" those drugs needed to support SafePill-1 development. Signatures of the expanded list of drugs needed to support SafePill-2 development is currently in process. (The names of drugs signatured to date are available on request.) Based upon testing conducted to date, and previous experience with development of related technologies, CDEX believes that expansion of the drug database is readily achievable. In addition, as new drugs are introduced to the market, they will be added to the SafePill System database, as warranted.
4. The CDEX Team
CDEX Inc. is a Nevada technology development company incorporated in July of 2001. The CDEX Board of Directors consists of Dr. B.D. Liaw, Malcolm H. Philips, Jr. and George E. Dials. All Board members have extensive track records of success. Mr. Philips also serves as the CEO and President of CDEX. The Senior Vice President of Operations is Tim Shriver, who has his roots in the commercial nuclear industry and brings strong project management skills and a deliberate, process oriented approach to problem solving developed out of an extensive Quality Assurance Management background. The Vice President of Business Operations is Mike Mergenthaler, who has supported technology startups in a number of areas including management of a global and extensive tech product rollout. The Principal Scientist, Dr. Wade Poteet (PhD from VPI in 1970), has focused his research in the area of advanced instrumentation in optics, electro-optics and detection technology. Dr. Laurence Marsteller (BS in Physics from Georgetown University, MS in Astronomy from Yale University and MD from University of Arizona) provides focus in applying the CDEX technology to the medical community. (the CDEX web site provides additional information www.cdex-inc.com.)
